Source: VIP Gloves
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • VIP Gloves (VIP) receives Australian Therapeutic Goods Administration (TGA) approval for its nitrile gloves
  • The TGA has registered VIP’s nitrile examination and treatment gloves as a class one medical device and has given approval to sell the gloves in Australia
  • This news follows USA Food and Drug Administration and European Union CE Mark approvals
  • VIP is up 7.50 per cent and is trading at 4.3 cents per share at 2:25 pm AEST

VIP Gloves (VIP) has received Australian Therapeutic Goods Administration (TGA) approval for its nitrile gloves.

Nitrile gloves are a synthetic rubber compound as opposed to latex.

The TGA has registered VIP’s nitrile examination and treatment gloves as a class one medical device and has given approval to sell the gloves in Australia.

This news follows USA Food and Drug Administration and European Union CE Mark approvals.

Chairman Joe Wong is pleased to have secured TGA approval.

“We have been advancing distribution agreements for the Australian
market in recent months and, with TGA accreditation now received, these
can be finalised enabling sales to commence in the coming months,” Dr Wong said.

“VIP Gloves continues to expand its international sales footprint to become
a global glove supplier, providing a platform to launch the company’s house
brands as capacity expands in the coming months when the additional two
production lines come online.”

VIP was up 7.50 per cent and was trading at 4.3 cents per share at 2:25 pm AEST.

VIP by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…